Recent Updates
Recently added Catalysts

Combination Therapy

Phase 3

Dyslipidemias | Small molecule | Metabolic |NewAmsterdam Pharma Company N.V.|Last Updated: Oct 7, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment407
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06005597Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesPHASE3 COMPLETED 407 — — Feb 1, 2024Oct 1, 2024Oct 7, 2025 - —
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Combination TherapyCOMBINATION_PRODUCTtablet; 10mg obicetrapib and 10mg ezetimibe fixed does combination
Monotherapy obicetrapibDRUGtablet; 10mg obicetrapib
Monotherapy ezetimibeDRUGcapsule; 10mg ezetimibe
Combination Therapy placeboOTHERtablet; no active ingredient
Obicetrapib PlaceboOTHERtablet; no active ingredient
Ezetimibe PlaceboOTHERcapsule; no active ingredient
Unlock Study Design Details